Genmab A/S (GMAB)
| Previous close | 27.69 |
| Open | 28.05 |
| Bid | 28.12 x 100 |
| Ask | 28.15 x 100 |
| Day's range | 27.97 - 28.26 |
| 52-week range | 26.32 - 42.72 |
| Volume | |
| Avg. volume | 565,968 |
| Market cap | 18.484B |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | 29.63 |
| EPS (TTM) | 0.95 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.15 |
- GuruFocus.com
Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
Explore key insights from Comstock Inc's Q1 2024 earnings, including significant revenue streams, strategic investments, and future financial strategies.
Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
COPENHAGEN, Denmark, April 29, 2024--Genmab A/S (Nasdaq: GMAB) and Pfizer Inc. (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. This FDA action converts the September 2021 accelerated approval of TIVDAK to a full approval. TIVDAK is the first anti
Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
NEW YORK & COPENHAGEN, Denmark, April 29, 2024--Pfizer Inc. (NYSE: PFE) and Genmab A/S (Nasdaq: GMAB) today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
